Across TCGA pan-cancer cohorts, AMZ2P2 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated AMZ2P2 data layer.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AMZ2P2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated AMZ2P2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CHOL show a favorable association.
LUAD, UCS, and KIRC are the cancer types where AMZ2P2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.